Cyber Monday saleUp to 70% OFF
MoonLake ImmunotherapeuticsMoonLake ImmunotherapeuticsMoonLake Immunotherapeutics

MoonLake Immunotherapeutics

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MLTX chart


Full chart

MLTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.28 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.29 USD
Net income (FY)
‪−36.01 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪52.81 M‬
Beta (1Y)
1.72

Employees


Employees (FY)
50
Change (1Y)
+30 +150.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−720.15 K‬ USD

About MoonLake Immunotherapeutics


Sector
Health Technology
CEO
Jorge Santos da Silva
Headquarters
Zug
Website
moonlaketx.com
Founded
2021
FIGI
BBG00XQZQTS9
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

MLTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MLTX is 51.55 USD — it has decreased by −7.52% in the past 24 hours. Watch MoonLake Immunotherapeutics stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MoonLake Immunotherapeutics stocks are traded under the ticker MLTX.
MLTX stock has fallen by −5.37% compared to the previous week, the month change is a 9.17% rise, over the last year MoonLake Immunotherapeutics has showed a 9.60% increase.
We've gathered analysts' opinions on MoonLake Immunotherapeutics future price: according to them, MLTX price has a max estimate of 104.00 USD and a min estimate of 55.00 USD. Watch MLTX chart and read a more detailed MoonLake Immunotherapeutics stock forecast: see what analysts think of MoonLake Immunotherapeutics and suggest that you do with its stocks.
MLTX reached its all-time high on Feb 12, 2024 with the price of 64.98 USD, and its all-time low was 4.25 USD and was reached on May 16, 2022. View more price dynamics on MLTX chart.
See other stocks reaching their highest and lowest prices.
MLTX stock is 6.84% volatile and has beta coefficient of 1.72. Track MoonLake Immunotherapeutics stock price on the chart and check out the list of the most volatile stocks — is MoonLake Immunotherapeutics there?
Today MoonLake Immunotherapeutics has the market capitalization of ‪3.24 B‬, it has decreased by −5.10% over the last week.
Yes, you can track MoonLake Immunotherapeutics financials in yearly and quarterly reports right on TradingView.
MoonLake Immunotherapeutics is going to release the next earnings report on Mar 24, 2025. Keep track of upcoming events with our Earnings Calendar.
MLTX earnings for the last quarter are −0.56 USD per share, whereas the estimation was −0.44 USD resulting in a −28.60% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about MoonLake Immunotherapeutics earnings.
MoonLake Immunotherapeutics revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MLTX net income for the last quarter is ‪−35.39 M‬ USD, while the quarter before that showed ‪−24.27 M‬ USD of net income which accounts for −45.84% change. Track more MoonLake Immunotherapeutics financial stats to get the full picture.
No, MLTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 4, 2024, the company has 50.00 employees. See our rating of the largest employees — is MoonLake Immunotherapeutics on this list?
Like other stocks, MLTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MoonLake Immunotherapeutics stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MoonLake Immunotherapeutics technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MoonLake Immunotherapeutics stock shows the buy signal. See more of MoonLake Immunotherapeutics technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.